Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy

DAEJEON,South Korea,Feb. 22,2021 --Curocell,Inc.,a clinical-stage biotech developing next-generation CAR-T (OVIS™) therapies,announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved its Phase 1/2 clinical study application for CRC01,CD19 CAR-T cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma(DLBCL). This study is expected to be initiated in the first half of 2021.

"We are excited to receive Korea's first IND clearance for a CAR-T therapy," said Gunsoo Kim,CEO of Curocell. "OVIS™ is a unique CAR-T platform that combines CAR-T with immune checkpoint receptor inhibition. This unique technology can be a breakthrough for patients who are difficult to treat with conventional CD19 CAR-T."

About CRC01

CRC01,recognized CD19 and is based on OVIS™,a first in class CAR-T platform co-developed with KAIST. OVIS™ downregulates PD1 and TIGIT in the same viral vector,designed to express a CAR protein,allowing cost-effective and simple manufacturing. Curocell holds the global development and commercial rights for CRC01 and OVIS™.

About Curocell

Curocell,based in Daejeon,is clinical-stage biotech innovating CAR-T therapies. Curocell is developing OVIS™ CAR-T therapies with the goal of reducing non-responding patients who receive CAR-T therapy. Curocell established a GMP facility in Samsung Medical Center,one of the largest cancer centers in Asia with 655 beds. For more information,visitcurocellbtx.com/en.

View original content:/news-releases/curocell-announces-korean-fda-clearance-of-the-ind-for-crc01-a-first-in-kind-immune-checkpoint-receptors-downregulated-cd19-car-t-therapy-301232233.html